NeuroOne Evo® sEEG electrodes: NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it successfully completed an animal feasibility study of its combination recording and ablation technology at T3 Labs and Georgia State/Georgia Tech Center for Advanced Brain Imaging in Atlanta Georgia under the guidance of Dr. Robert Gross of Emory University. The study evaluated the ability of the NeuroOne Evo® sEEG electrodes to record brain activity and then ablate brain tissue using radiofrequency thermocoagulation in a porcine model.
The Evo ablation electrode represents the Company’s first development effort for therapeutic technology and is expected to be the next product offering in its portfolio pending FDA clearance. The product is designed to provide the ability to both identify problematic areas of the brain causing seizures as well as ablate brain tissue to alleviate these symptoms. This would represent a major advancement in neurosurgery, given that patients must first undergo the diagnostic surgery and then schedule a future second surgery to ablate the problematic tissue.
Dr. Robert Gross of Emory says, “This pilot study will provide important data to inform the development of this technological solution that has the potential to improve treatment efficacy and patient comfort.”
“We are encouraged and excited by the results of this animal feasibility study. This technology offers the potential to perform two separate procedures using the same device during one hospital stay which we believe is a safer and more cost-effective approach for both the patient, health care provider and health care facility. Today, a patient often needs to have two separate hospitalizations for two separate surgeries typically with months between both procedures. Coupled with our recent partnership with RBC Medical to develop the radio frequency hardware, we are excited about the potential to offer a complete system for our customers” says Dave Rosa, CEO of NeuroOne.
Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.